logo-loader
viewArgosy Minerals Ltd

Result of AGM

/**/ sup{font-size:80%}h1{margin-top:0cm;margin-right:0cm;margin-bottom:13.0pt;margin-left:0cm;line-height:13.0pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h2{margin-top:13.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:35.4pt;text-align:justify;text-indent:-35.4pt;line-height:18.0pt;text-autospace:none;font-size:13.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin-top:13.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:70.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-35.4pt;line-height:18.0pt;text-autospace:none;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:bold;font-div:italic;}h4{margin-top:13.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:106.2pt;margin-bottom:.0001pt;text-align:justify;text-indent:-35.4pt;line-height:18.0pt;text-autospace:none;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;font-div:italic;}h5{margin-top:6.5pt;margin-right:0cm;margin-bottom:0cm;margin-left:141.6pt;margin-bottom:.0001pt;text-align:justify;text-indent:-35.4pt;text-autospace:none;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:177.0pt;text-align:justify;text-indent:-35.4pt;text-autospace:none;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;}p{margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .el{size:595.3pt 841.9pt;margin:51.05pt 2.0cm 49.65pt 2.0cm;}div.el{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";}span.ew{font-size:10.0pt;font-family:"Arial","sans-serif"}p.ey{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.ez{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";punctuation-wrap: hanging; text-align: center; text-autospace: ideograph-numeric ideograph-other}span.eu{font-size:10.0pt; font-family:"Arial","sans-serif"}p.fa{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: center; text-autospace: ideograph-numeric ideograph-other}span.es{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.fb{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: left; text-autospace: ideograph-numeric ideograph-other} p.fc{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";text-autospace:ideograph-numeric ideograph-other}p.fd{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.fe{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: left; text-autospace: ideograph-other}span.en{font-size:10.0pt;font-family: "Arial","sans-serif"} /**/
RNS Number : 6549I
Allergy Therapeutics PLC
27 November 2018
 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

27 November 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, at its Annual General Meeting held this morning, all resolutions were duly passed.

 

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

[email protected]

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGFEFFDWFASEFF

Quick facts: Argosy Minerals Ltd

Price: 0.065

Market: ASX
Market Cap: $66.01 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Argosy signs binding agreement to acquire strategic US lithium brine project

Argosy Minerals Limited (ASX:AGY) managing director Jerko Zuvela updates Proactive Investors on the signing of a binding agreement to acquire a strategic lithium project in the US. The sale agreement provides for Argosy to acquire the Tonopah Lithium Brine Project in Nevada, just 4 kilometres...

on 16/8/19